• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Pardes Biosciences Inc.

    8/31/23 9:19:07 AM ET
    $PRDS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PRDS alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-40067
    Issuer: PARDES BIOSCIENCES, INC.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 2173 Salk Avenue, Suite 250 PMB#052
    Carlsbad CALIFORNIA 92008
    Telephone number: 415-649-8758
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-08-31 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PRDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRDS

    DatePrice TargetRatingAnalyst
    7/18/2023Mkt Outperform → Mkt Perform
    JMP Securities
    3/15/2022Outperform
    SVB Leerink
    1/18/2022$25.00Buy
    Jefferies
    More analyst ratings

    $PRDS
    Leadership Updates

    Live Leadership Updates

    See more
    • Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

      Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

      1/17/23 7:00:00 AM ET
      $ASMB
      $PRDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors

      CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19 disease, today announced the appointments of Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to its Board of Directors. "As we advance PBI-0451 into a Phase 2 study, I am delighted to welcome both Laurie and John to our Board and look forward to leveraging their deep experience and insights as we take the next steps in development," said Tom Wiggans, Chief Executive Officer and Chair of the B

      9/14/22 8:00:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board

      Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be beneficial to Pardes as the company rapidly progresses to late-stage development and regulatory activities, as well as the initial phases of commercialization build-out Uri Lopatin, M.D. to transition to Chief Scientific & Strategic Advisor; Mark Auerbach to transition from Chairman to Board Director CARLSBAD, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral a

      3/2/22 4:30:00 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares

      4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

      8/31/23 5:22:32 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Wiggans Thomas G closing all direct ownership in the company

      4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

      8/31/23 2:55:56 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Varney Michael David closing all direct ownership in the company

      4 - PARDES BIOSCIENCES, INC. (0001822711) (Issuer)

      8/31/23 2:54:23 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Financials

    Live finance-specific insights

    See more
    • Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022

      PBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2 PBI-0451 has been generally well-tolerated and has shown good oral bioavailability Company to host conference call and webcast Tuesday, February 15, 2022 at 3:00 p.m. PT / 6:00 p.m. ET CARLSBAD, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that interim clin

      2/14/22 7:30:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • Pardes Biosciences to Host Virtual Investor Event

      CARLSBAD, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e. COVID-19), today announced that a virtual investor event will be hosted by the company's management team following the presentation of clinical data from the ongoing PBI-0451 Phase 1 trial at the 29th Conference On Retroviruses And Opportunistic Infections (CROI) 2022. The conference call and webcast will take place on Tuesday, February 15 at 3:00 p.m. PT / 6:00 p.m. ET. Individuals in

      2/9/22 7:00:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pardes Biosciences Announces Closing of Tender Offer

      CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes' outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent value right (each, a CVR and each CVR together with the Cash Amount, the Offer Price) associated with any future monetization of its COVID-19 antiviral portfolio and related intellectual property.

      8/31/23 8:15:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

      As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (NASDAQ:PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share in cash, plus a non-tradeable contingent value right (the "CVR") associated with any future monetization of Pardes' COVID-19 antiviral portfolio and related intellectual property. Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes' out

      8/28/23 11:33:00 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

      As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (NASDAQ:PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share (the "Additional Price Per Share"), plus a non-tradeable contingent value right (the "CVR") associated with any future monetization of Pardes' COVID-19 antiviral portfolio and related intellectual property. Pursua

      8/17/23 5:43:00 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)

      SC 13D/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

      8/31/23 5:17:40 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Pardes Biosciences Inc.

      SC 13G - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

      8/14/23 4:31:01 PM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)

      SC 13D/A - PARDES BIOSCIENCES, INC. (0001822711) (Subject)

      7/17/23 7:55:13 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Pardes Biosciences Inc.

      15-12G - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

      9/11/23 8:00:13 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Pardes Biosciences Inc.

      EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

      9/1/23 12:15:04 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Pardes Biosciences Inc.

      EFFECT - PARDES BIOSCIENCES, INC. (0001822711) (Filer)

      9/1/23 12:15:24 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care

    $PRDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pardes Biosciences downgraded by JMP Securities

      JMP Securities downgraded Pardes Biosciences from Mkt Outperform to Mkt Perform

      7/18/23 7:42:34 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • SVB Leerink initiated coverage on Pardes Biosciences

      SVB Leerink initiated coverage of Pardes Biosciences with a rating of Outperform

      3/15/22 10:07:39 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • Jefferies initiated coverage on Pardes Biosciences with a new price target

      Jefferies initiated coverage of Pardes Biosciences with a rating of Buy and set a new price target of $25.00

      1/18/22 8:36:11 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care